Tirzepatide

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Tirzepatide

Examples of brand names: Mounjaro [EU/DE]

ATC code: A10BX16

Main use (for orientation): Diabetes; obesity

Documented research summary

Within the documented search scope, no sufficiently attributable cannabinoid pair is established for Tirzepatide. The structured assessment distinguishes documented drug context from the absence of specific interaction evidence. Missing data do not establish safety.

Uncertainties and limitations

Abstract reassessed; complete PMC text blocked on repeat retrieval. No cannabis causality or frequency can be inferred. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: Peptide breakdown, beta oxidation and amide hydrolysis; delayed gastric emptying.

Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.

Clinical interpretation: Severe symptoms in a single case do not establish a causal tirzepatide–cannabinoid interaction.

Context: Case report after dose escalation with gastrointestinal symptoms, sepsis and metabolic decompensation; relevant concomitant factors. Cannabis details from the existing screening remain context.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [VD_LABEL_D0259]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: Peptide breakdown, beta oxidation and amide hydrolysis; delayed gastric emptying.

Source: ZEPBOUND (TIRZEPATIDE) INJECTION, SOLUTION ZEPBOUND (TIRZEPATIDE) INJECTION, SOLUTION ZEPBOUND KWIKPEN (TIRZEPATIDE) INJECTION, SOLUTION [ELI LILLY AND COMPANY] – DailyMed SPL [VD_LABEL_D0259]

Source role [VD_MED_41458667]: Single-case context, no established cannabinoid causality

Statement supported: Severe symptoms after tirzepatide escalation with concomitant factors; no isolated interaction assessment.

Source: Intractable Vomiting in the Setting of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and Cannabis Usage. [VD_MED_41458667]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. Abstract reassessed; complete PMC text blocked on repeat retrieval. No cannabis causality or frequency can be inferred.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[VD_LABEL_D0259] ZEPBOUND (TIRZEPATIDE) INJECTION, SOLUTION ZEPBOUND (TIRZEPATIDE) INJECTION, SOLUTION ZEPBOUND KWIKPEN (TIRZEPATIDE) INJECTION, SOLUTION [ELI LILLY AND COMPANY] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2026

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VD_MED_41458667] Intractable Vomiting in the Setting of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and Cannabis Usage.

Original source / bibliographic reference

Authors: DesRochers P, Kaiser L, Lee S, Perchetti GA, Lazarescu R.

Year: 2025

Source type: Journal Article; Case Reports; case-report

DOI: 10.7759/cureus.97851

PMID: 41458667

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility